Therapeutic Asset Ratings

515 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Irinotecan Lung Squamous Cell Carcinoma	AstraZeneca	P3	BB (66)
Surovatamig Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV	AstraZeneca	P3	BB (66)
(+)-VINCRISTINE Lung Squamous Cell Carcinoma	AstraZeneca	P3	BB (66)
VOLITINIB Locally Advanced Papillary Renal Cell Carcinoma	AstraZeneca	P3	BB (66)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Prostate Cancer	AstraZeneca	P4	BB (65)
Datopotamab Deruxtecan Stomatitis	AstraZeneca	P4	BB (65)
Posaconazole Acute Myeloid Leukemia	AstraZeneca	P4	BB (65)
Osimertinib Carcinoma	AstraZeneca	P3	BB (65)
DEXAMETHASONE Stomatitis	AstraZeneca	P4	BB (64)
Posaconazole Myelodysplastic Syndromes	AstraZeneca	P4	BB (64)
RADIUM RA-223 Metastatic Castration-resistant Prostate Cancer	AstraZeneca	P4	BB (64)
FLUOROURACILUM Esophageal Squamous Cell Carcinoma	AstraZeneca	P3	BB (64)
VOLITINIB Carcinoma, Renal Cell	AstraZeneca	P3	BB (64)
azd2389 Hepatic Cirrhosis	AstraZeneca	P2	BB (64)
azd2389 Liver Fibrosis	AstraZeneca	P2	BB (64)
azd2693 Non-alcoholic Steatohepatitis	AstraZeneca	P2	BB (64)
azd9550 Obesity or Overweight	AstraZeneca	P2	BB (64)
Ceralasertib Advanced Solid Tumours	AstraZeneca	P2	BB (64)
Olaparib Breast	AstraZeneca	P2	BB (64)
Olaparib Castration-Resistant Prostate Carcinoma	AstraZeneca	P2/3	BB (64)
Atirmociclib Breast Cancer	AstraZeneca	P3	B (63)
Durvalumab Papillary Renal Cell Carcinoma	AstraZeneca	P3	B (63)
Rilvegostomig Non-small Cell Lung Cancer	AstraZeneca	P3	B (63)
su011248 Kidney Diseases	AstraZeneca	P3	B (63)
Surovatamig Large B-cell Lymphoma	AstraZeneca	P3	B (63)

Showing 26 to 50 of 515 assets